SOLTF (Nxera Pharma Co) GF Score: 84/100 (As of Jul. 02, 2026) — 24% Above Median


SOLTF Nxera Pharma Co Ltd SOLTF
84 GF Score
Price $6.00
GF Value $7.83
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co GF Score?

Nxera Pharma Co SOLTF -5.81% 84 GF Score is 84 as of Jul. 02, 2026, which is 24% above its 10-year median of 68.00. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.83 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Nxera Pharma Co has the GF Score of 84, which implies that the company might have Good outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 6/10
3. Growth Rank : 9/10
4. GF Value Rank : 8/10
5. Momentum Rank : 8/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Nxera Pharma Co might have Good outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Nxera Pharma Co  (OTCPK:SOLTF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Nxera Pharma Co GF Score Related Terms

SOLTF vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Nxera Pharma Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's GF Score distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's GF Score falls into.


SOLTF
84GF Score
Nxera Pharma Co Ltd SOLTF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 84 mean?
Nxera Pharma Co (SOLTF) has a GF Score of 84 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nxera Pharma Co and its competitors. This is 24% above median its historical median of 68.00. Over the past decade, Nxera Pharma Co's GF Score has ranged from 29.00 to 84.00.
Is Nxera Pharma Co's GF Score too high?
Nxera Pharma Co's current GF Score of 84 is 24% above median its 10-year median of 68.00. Over the past 10 years, this metric has ranged from a low of 29.00 to a high of 84.00. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's GF Score compare to VRTX and REGN?
Nxera Pharma Co's GF Score of 84 can be compared against companies in the Biotechnology industry. Historically, Nxera Pharma Co's own GF Score has ranged from 29.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current GF Score is 84, which is 24% above median its own 10-year median of 68.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.83, compared to a current price of $6.00 — trading 23.4% below its estimated fair value. The current GF Score is 84, which is 24% above median its 10-year median of 68.00. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current GF Score is 84 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $6.00 is trading 23.4% below its estimated GF Value™ of $7.83. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

  • GF Score: 84 (24% above median its 10-year median of 68.00)
  • GF Value™: $7.83 vs. price of $6.00 (23.4% below fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Other Exchanges 4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
84GF Score

Get the complete analysis for SOLTF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.00
Price
$7.83
GF Value